Cargando…

Pharmacogenetic Study of Deferasirox, an Iron Chelating Agent

Transfusion-associated iron overload induces systemic toxicity. Deferasirox, a convenient long acting oral agent, has recently been introduced in clinical practice with a promising efficacy. But there are some patients who experience drug-related toxicities and cannot tolerate it. To investigate eff...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Ji Won, Kang, Hyoung Jin, Choi, Ji-Yeob, Kim, Nam Hee, Jang, Mi Kyung, Yeo, Chang-Woo, Lee, Sang Seop, Kim, Hyery, Park, June Dong, Park, Kyung Duk, Shin, Hee Young, Shin, Jae-Gook, Ahn, Hyo Seop
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667856/ https://www.ncbi.nlm.nih.gov/pubmed/23737969 http://dx.doi.org/10.1371/journal.pone.0064114

Ejemplares similares

Pharmacogenetic Analysis of Pediatric Patients with Acute Lymphoblastic Leukemia: A Possible Association between Survival Rate and ITPA Polymorphism
por: Kim, Hyery, et al.
Publicado: (2012)

Successful Treatment of Primary Central Nervous System Lymphoma without Irradiation in Children: Single Center Experience
por: Yoon, Jong Hyung, et al.
Publicado: (2012)

Chronic graft versus host disease with small bowel obstruction after unrelated hematopoietic stem cell transplantation in a patient with acute myeloid leukemia
por: Yoon, Ju Young, et al.
Publicado: (2012)

Successful mobilization using a combination of plerixafor and G-CSF in pediatric patients who failed previous chemomobilization with G-CSF alone and possible complications of the treatment
por: Hong, Kyung Taek, et al.
Publicado: (2012)

Treatment outcomes in children with Burkitt lymphoma and L3 acute lymphoblastic leukemia treated using the lymphoma malignancy B protocol at a single institution
por: Park, Eun Sil, et al.
Publicado: (2011)

Effects of oral iron chelator deferasirox on human malignant lymphoma cells
por: Choi, Jong Gwon, et al.
Publicado: (2012)

Clinical Characteristics of Pediatric Thalassemia in Korea: A Single Institute Experience
por: Hong, Che Ry, et al.
Publicado: (2013)

Double umbilical cord blood transplantation for children and adolescents
por: Kang, Hyoung Jin, et al.
Publicado: (2010)

Targeted busulfan and fludarabine-based conditioning for bone marrow transplantation in chronic granulomatous disease
por: Ju, Hee Young, et al.
Publicado: (2016)

ALK Protein Expression Is Related to Neuroblastoma Aggressiveness But Is Not Independent Prognostic Factor
por: Lee, Ji Won, et al.
Publicado: (2018)

Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells
por: Kim, Dae Sik, et al.
Publicado: (2016)

Association of systolic blood pressure drop with intravenous administration of itraconazole in children with hemato-oncologic disease
por: Lee, Hyeong Jin, et al.
Publicado: (2015)

Hemophagocytic lymphohistiocytosis diagnosed by brain biopsy
por: Ju, Hee Young, et al.
Publicado: (2015)

Iron Chelation Therapy with Deferasirox in the Management of Iron Overload in Primary Myelofibrosis
por: Elli, Elena Maria, et al.
Publicado: (2014)

Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma
por: Saeki, Issei, et al.
Publicado: (2016)

From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox
por: Palumbo, Giuseppe A., et al.
Publicado: (2021)

Successful Salvage Unrelated Umbilical Cord Blood Transplantation with Two Units After Engraftment Failure with Single Unit in Severe Aplastic Anemia
por: Lee, Ji Won, et al.
Publicado: (2009)

Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib
por: Yamamoto, Naoki, et al.
Publicado: (2016)

Pharmacometabolomics for predicting variable busulfan exposure in paediatric haematopoietic stem cell transplantation patients
por: Kim, Bora, et al.
Publicado: (2017)

High Transcript Level of FLT3 Associated with High Risk of Relapse in Pediatric Acute Myeloid Leukemia
por: Kang, Hyoung Jin, et al.
Publicado: (2010)

Clinical Outcome of Relapsed or Refractory Burkitt Lymphoma and Mature B-Cell Lymphoblastic Leukemia in Children and Adolescents
por: Kim, Hyery, et al.
Publicado: (2014)

Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox
por: Amano, Shogo, et al.
Publicado: (2020)

Outcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study
por: Koh, Kyung-Nam, et al.
Publicado: (2017)

Retrospective Analysis of Peripheral Blood Stem Cell Transplantation for the Treatment of High-Risk Neuroblastoma
por: Kim, Eun Kyung, et al.
Publicado: (2007)

Iron Chelation Therapy With Deferasirox in Sickle Cell Disease With End-Stage Renal Disease
por: Raj, Ashok, et al.
Publicado: (2022)

Correction: Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox
por: Amano, Shogo, et al.
Publicado: (2023)

Respiratory Viral Infections after Hematopoietic Stem Cell Transplantation in Children
por: Choi, Jae Hong, et al.
Publicado: (2013)

Extra-cranial Malignant Rhabdoid Tumor in Children: A Single Institute Experience
por: Hong, Che Ry, et al.
Publicado: (2015)

Improvement of Induction Remission Rate by Modifying the Dose of Idarubicin for Relapsed Childhood Acute Lymphoblastic Leukemia
por: Yoon, Jong Hyung, et al.
Publicado: (2009)

Association between Genetic Polymorphisms of CYP2D6 and Outcomes in Breast Cancer Patients with Tamoxifen Treatment
por: Park, Hyung Seok, et al.
Publicado: (2011)

Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study
por: Taher, Ali, et al.
Publicado: (2009)

Combination Iron Chelation Therapy with Deferiprone and Deferasirox in Iron-Overloaded Patients with Transfusion-Dependent β-Thalassemia Major
por: Karami, Hossein, et al.
Publicado: (2017)

Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation
por: Finkenstedt, Armin, et al.
Publicado: (2010)

Low oxygen tension reverses antineoplastic effect of iron chelator deferasirox in human glioblastoma cells
por: Legendre, Claire, et al.
Publicado: (2016)

Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox
por: Olivieri, Nancy F., et al.
Publicado: (2019)

Visual Prognosis of Retinoblastoma in the Posterior Pole Treated with Primary Chemotherapy Plus Local Treatments
por: Kim, Jae Min, et al.
Publicado: (2010)

Improved Survival in Patients with Recurrent Wilms Tumor: the Experience of the Seoul National University Children's Hospital
por: Park, Eun Sil, et al.
Publicado: (2006)

Iron Chelation Therapy with Deferasirox Results in Improvement of Liver Enzyme Level in Patients with Iron Overload-Associated Liver Dysfunction
por: Miura, Yasuo, et al.
Publicado: (2010)

Normal pregnancy in a patient with β-thalassaemia major receiving iron chelation therapy with deferasirox (Exjade®)
por: Vini, Dimitra, et al.
Publicado: (2011)

Deferasirox, an oral iron chelator, with gemcitabine synergistically inhibits pancreatic cancer cell growth in vitro and in vivo
por: Shinoda, Shuhei, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_o2ff0ho2vt2ugdae4gvil992cg